Bharat Biotech International Ltd on Wednesday announced a licensing agreement with Washington University School of Medicine in the US for a single dose intranasal vaccine for covid-19 based on a novel chimpanzee adenovirus.
The pact gives the Hyderabad-based vaccine developer the rights to distribute the vaccine in all markets except the US, Japan and Europe.Under the pact, phase I trials will take place in the university’s Vaccine and Treatment Evaluation Unit, while Bharat Biotech will undertake further stages of clinical trials in India and large-scale manufacturing of the vaccine at its facility in Genome Valley, Hyderabad.“We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated.